Novocure Ltd (NVCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novocure Ltd (NVCR) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.57 Million) by net assets ($341.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Novocure Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Novocure Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Novocure Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Novocure Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novocure Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Csg Smart Science&Technology Co Ltd
SHE:300222
|
0.084x |
|
WEIBO CORP. A
F:2WB
|
N/A |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
0.055x |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
-0.073x |
|
Bafang Electric Suzhou Co Ltd
SHG:603489
|
0.017x |
|
Bristow Group Inc
NYSE:VTOL
|
0.022x |
|
The Wendy’s Co
NASDAQ:WEN
|
0.590x |
|
ATAI Life Sciences NV
XETRA:9VC
|
-0.145x |
Annual Cash Flow Conversion Efficiency for Novocure Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Novocure Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Novocure Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $360.18 Million | $-26.37 Million | -0.073x | +63.81% |
| 2023-12-31 | $362.50 Million | $-73.34 Million | -0.202x | -389.89% |
| 2022-12-31 | $441.17 Million | $30.79 Million | 0.070x | -65.38% |
| 2021-12-31 | $410.49 Million | $82.76 Million | 0.202x | -3.11% |
| 2020-12-31 | $476.53 Million | $99.15 Million | 0.208x | +70.23% |
| 2019-12-31 | $217.79 Million | $26.62 Million | 0.122x | +835.72% |
| 2018-12-31 | $112.26 Million | $-1.86 Million | -0.017x | +94.31% |
| 2017-12-31 | $113.56 Million | $-33.13 Million | -0.292x | +61.40% |
| 2016-12-31 | $142.34 Million | $-107.59 Million | -0.756x | -89.80% |
| 2015-12-31 | $250.82 Million | $-99.88 Million | -0.398x | +47.50% |
| 2014-12-31 | $97.88 Million | $-74.24 Million | -0.759x | -147.18% |
| 2013-12-31 | $171.78 Million | $-52.72 Million | -0.307x | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in br… Read more